Related Experiment Videos
Antibiotics as disease modifiers in arthritis
M Kloppenburg1, F C Breedveld, A M Miltenburg
1Department of Rheumatology, University Hospital, Leiden, The Netherlands.
Abstract:
The tetracyclines, especially minocycline, are supposed to have antiarthritic properties. Their efficacy has been tested in open clinical studies on RA patients. Recently a double-blind placebo-controlled trial was performed which revealed the antirheumatic properties of minocycline. The mode of action of the tetracyclines in arthritis is unknown, but could be linked to the immunosuppressive activity seen in vitro. The antiproliferative effect of minocycline in cloned synovial T-cells is demonstrated; moreover IFN-gamma production in cloned synovial T-cells is inhibited by minocycline.
Insights
Minocycline, a tetracycline antibiotic, demonstrates antirheumatic properties in rheumatoid arthritis (RA) patients. This study highlights its potential therapeutic effects by inhibiting T-cell proliferation and interferon-gamma production in synovial cells.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Tetracyclines, particularly minocycline, are investigated for potential antiarthritic effects.
- Previous open clinical studies suggested efficacy in rheumatoid arthritis (RA) patients.
- The precise mechanism of action for tetracyclines in arthritis remained largely unknown.
Purpose of the Study:
- To evaluate the antirheumatic properties of minocycline in a rigorous clinical trial.
- To explore the potential immunomodulatory mechanisms underlying minocycline's effects in arthritis.
- To investigate the impact of minocycline on T-cell activity within the synovial environment.
Main Methods:
- A double-blind, placebo-controlled trial was conducted on RA patients.
- In vitro studies assessed the antiproliferative effects of minocycline on cloned synovial T-cells.
- Interferon-gamma (IFN-gamma) production by cloned synovial T-cells was measured in the presence of minocycline.
Main Results:
- The double-blind trial confirmed the antirheumatic efficacy of minocycline.
- Minocycline demonstrated an antiproliferative effect on cloned synovial T-cells.
- Minocycline significantly inhibited IFN-gamma production in these T-cells, suggesting immunosuppressive activity.
Conclusions:
- Minocycline exhibits confirmed antirheumatic properties, supported by clinical trial data.
- The observed effects may be linked to minocycline's in vitro immunosuppressive activities.
- Targeting T-cell proliferation and IFN-gamma production represents a potential mechanism for minocycline's therapeutic benefit in arthritis.